Bullous pemphigoid

From WikiProjectMed
Jump to navigation Jump to search
Bullous pemphigoid
Childhood bullous pemphigoid (DermNet NZ immune-bullous-pemphigoid-3).jpg
SymptomsTense blisters, itch, red patches, urticaria[1]
Usual onsetAge 65 to 75-years[1]
TypesVesicular pemphigus, pemphigoid vegetans, polymorphic pemphigus, pemphigoid excoriée, pemphigoid nodularis[2]
Risk factorsRadiotherapy,[1] furosemide[2]
Diagnostic methodAppearance, blood test, biopsy, immunofluoresence[1]
MedicationCorticosteroids, azathioprine, mycophenolate[3]
FrequencyAge 65 to 75-years[1]

Bullous pemphigoid is a blistering skin disease.[1] There are characteristically several large firm blisters on an urticarial base and with a tendency to occur in the groin, underarms, thighs, shins and inner surface of the arms.[1] It is usually itchy and there may be red and urticarial patches with central clearing.[1] Blisters may not always be present, especially early on in the course of the disease.[1] They may look like targets.[1] When the blisters burst, the skin may appear sore before it heals.[1]

It is an autoimmune disease.[1] Variants include vesicular pemphigus, pemphigoid vegetans, polymorphic pemphigus, pemphigoid excoriée, pemphigoid nodularis.[2] Large blisters form in the space between the epidermal and dermal skin layers. The disorder is a type of pemphigoid. It is classified as a type II hypersensitivity reaction, with the formation of anti-hemidesmosome antibodies.

It may occur at sites of radiation treatment, particularly in people with breast cancer.[4] It may occur over a burn or where there are patches of psoriasis.[1] Other triggers include medicines such as furosemide.[2]

Diagnosis is by its appearance and confirmed by biopsy and immunofluorescence.[1] In young girls with vulval involvement of BP, it may look like child abuse.[1] Other conditions that may appear similar include lichen planus pemphigoides and prurigo nodularis.[1] Treatment is generally with corticosteroids to begin with, with azathioprine and mycophenolate for longer term management.[3]

It occurs most often in the elderly with an onset typically around age 65 to 75-years.[1] When occurring in children, it typically occurs before the first birthday and lasts around 5-months.[1]

Signs and symptoms

Clinically, the earliest lesions may appear as a hives-like red raised rash, but could also appear dermatitic, targetoid, lichenoid, nodular, or even without a rash (essential pruritus).[5] Tense bullae eventually erupt, most commonly at the inner thighs and upper arms, but the trunk and extremities are frequently both involved.[1] Any part of the skin surface can be involved.[1] Oral lesions are present in a minority of cases.[6] The disease may be acute, but can last from months to years with periods of exacerbation and remission.[7] Several other skin diseases may have similar symptoms. However, milia are more common with epidermolysis bullosa acquisita, because of the deeper antigenic targets. A more ring-like configuration with a central depression or centrally collapsed bullae may indicate linear IgA disease. Nikolsky's sign is negative, unlike pemphigus vulgaris, where it is positive.[1]


In most cases of bullous pemphigoid, no clear precipitating factors are identified.[6] Potential precipitating events that have been reported include exposure to ultraviolet light and radiation therapy.[6][8] Onset of pemphigoid has also been associated with certain drugs, including furosemide, nonsteroidal anti-inflammatory agents, DPP-4 inhibitors, captopril, penicillamine, and antibiotics.[8]


The bullae are formed by an immune reaction, initiated by the formation of IgG[9] autoantibodies targeting dystonin, also called bullous pemphigoid antigen 1,[10] and/or type XVII collagen, also called bullous pemphigoid antigen 2,[11] which is a component of hemidesmosomes. A different form of dystonin is associated with neuropathy.[10] Following antibody targeting, a cascade of immunomodulators results in a variable surge of immune cells, including neutrophils, lymphocytes and eosinophils coming to the affected area. Unclear events subsequently result in a separation along the dermoepidermal junction and eventually stretch bullae.[citation needed]


Micrograph of bullous pemphigoid. Subepidermal blistering [solid arrows in (A,B)] and influx of inflammatory cells including eosinophils and neutrophils in thedermis [solid arrow (C)] and blister cavity [dashed arrows (C)]. In (C) also deposition of fibrin is noted (asterisks).[12]

Diagnosis consist of at least 2 positive results out of 3 criteria (2-out-of-3 rule): (1) pruritus and/or predominant cutaneous blisters, (2) linear IgG and/or C3c deposits (in an n- serrated pattern) by direct immunofluorescence microscopy (DIF) on a skin biopsy specimen, and (3) positive epidermal side staining by indirect immunofluorescence microscopy on human salt-split skin (IIF SSS) on a serum sample.[13] Routine H&E staining or ELISA tests do not add value to initial diagnosis.[citation needed]


Treatments include topical steroids such as clobetasol, and halobetasol which in some studies have proven to be equally effective as systemic, or pill, therapy and somewhat safer.[6] However, in difficult-to-manage or widespread cases, systemic prednisone and powerful steroid-free immunosuppressant medications, such as methotrexate, azathioprine or mycophenolate mofetil, may be appropriate.[6][14] Some of these medications have the potential for severe adverse effects such as kidney and liver damage, increased susceptibility to infections, and bone marrow suppression.[15] Antibiotics such as tetracycline or erythromycin may also control the disease, particularly in patients who cannot use corticosteroids.[14] The anti-CD20 monoclonal antibody rituximab has been found to be effective in treating some otherwise refractory cases of pemphigoid.[16] A 2010 meta-analysis of 10 randomized controlled trials showed that oral steroids and potent topical steroids are effective treatments, although their use may be limited by side-effects, while lower doses of topical steroids are safe and effective for treatment of moderate bullous pemphigoid.[15]

IgA-mediated pemphigoid can often be difficult to treat even with usually effective medications such as rituximab.[17]


Bullous pemphigoid may be self-resolving in a period ranging from several months to many years even without treatment.[6] Poor general health related to old age is associated with a poorer prognosis.[6]


It occurs most often in the elderly with an onset typically around age 65 to 75-years.[1] Its estimated frequency is seven to 14 cases per million per year, but has been reported to be as high as 472 cases per million per year in Scottish men older than 85.[6] At least one study indicates the incidence might be increasing in the United Kingdom.[18] Some sources report it affects men twice as frequently as women,[14] while others report no difference between the sexes.[6]

Many mammals can be afflicted, including dogs, cats, pigs, and horses, as well as humans. It is very rare in dogs; on average, three cases are diagnosed around the world each year.[citation needed]


Animal models of bullous pemphigoid have been developed using transgenic techniques to produce mice lacking the genes for the two known autoantigens, dystonin and collagen XVII.[10][11]

See also


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 James, William D.; Elston, Dirk; Treat, James R.; Rosenbach, Misha A.; Neuhaus, Isaac (2020). "21. Chronic blistering dermatoses". Andrews' Diseases of the Skin: Clinical Dermatology (13th ed.). Edinburgh: Elsevier. p. 461-463. ISBN 978-0-323-54753-6. Archived from the original on 2022-03-16. Retrieved 2022-03-15.
  2. 2.0 2.1 2.2 2.3 Johnstone, Ronald B. (2017). "6. Vesiculobullous reaction pattern". Weedon's Skin Pathology Essentials (2nd ed.). Elsevier. pp. 88–133. ISBN 978-0-7020-6830-0. Archived from the original on 2021-05-25. Retrieved 2022-03-18.
  3. 3.0 3.1 Wakelin, Sarah H. (2020). "22. Dermatology". In Feather, Adam; Randall, David; Waterhouse, Mona (eds.). Kumar and Clark's Clinical Medicine (10th ed.). Elsevier. pp. 686–687. ISBN 978-0-7020-7870-5. Archived from the original on 2022-03-21. Retrieved 2022-03-21.
  4. Johnstone, Ronald B. (2017). "5. Spongiotic reaction pattern". Weedon's Skin Pathology Essentials (2nd ed.). Elsevier. pp. 68–87. ISBN 978-0-7020-6830-0. Archived from the original on 2021-05-25. Retrieved 2022-03-18.
  5. Cozzani E, Gasparini G, Burlando M, Drago F, Parodi A (May 2015). "Atypical presentations of bullous pemphigoid: Clinical and immunopathological aspects". Autoimmunity Reviews. 14 (5): 438–45. doi:10.1016/j.autrev.2015.01.006. PMID 25617817.
  6. 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 Culton DA, Liu Z, Diaz LA (17 October 2007). "Chapter 54. Bullous Pemphigoid". In Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ (eds.). Fitzpatrick's Dermatology In General Medicine, Two Volumes (7th ed.). Mcgraw-hill. ISBN 978-0-07-146690-5. Archived from the original on 4 July 2014. Retrieved July 21, 2012.
  7. Longo, D (2012). Harrison's Principles of Internal Medicine. p. 427. ISBN 9780071632447.
  8. 8.0 8.1 Chan LS (2011). "Bullous Pemphigoid". EMedicine Reference. Archived from the original on 2011-11-10. Retrieved 2011-09-25.
  9. "Dorlands Medical Dictionary:bullous pemphigoid". Retrieved 2010-06-24.[permanent dead link]
  10. 10.0 10.1 10.2 Online Mendelian Inheritance in Man (OMIM): DYSTONIN; DST - 113810
  11. 11.0 11.1 Online Mendelian Inheritance in Man (OMIM): COLLAGEN, TYPE XVII, ALPHA-1; COL17A1 - 113811
  12. Giang, Jenny; Seelen, Marc A. J.; van Doorn, Martijn B. A.; Rissmann, Robert; Prens, Errol P.; Damman, Jeffrey (2018). "Complement Activation in Inflammatory Skin Diseases". Frontiers in Immunology. 9: 639. doi:10.3389/fimmu.2018.00639. ISSN 1664-3224. PMC 5911619. PMID 29713318.
  13. Meijer JM, Diercks GF, de Lang EW, Pas HH, Jonkman MF (December 2018). "Assessment of diagnostic strategy for early recognition of bullous and nonbullous variants of pemphigoid". JAMA Dermatol. 155 (2): 158–165. doi:10.1001/jamadermatol.2018.4390. PMC 6439538. PMID 30624575.
  14. 14.0 14.1 14.2 ""Bullous Pemphigoid." Quick Answers to Medical Diagnosis and Therapy". Archived from the original on 2001-07-26. Retrieved 2012-07-21.
  15. 15.0 15.1 Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP (October 2010). "Interventions for bullous pemphigoid". The Cochrane Database of Systematic Reviews (10): CD002292. doi:10.1002/14651858.CD002292.pub3. PMC 7138251. PMID 20927731.
  16. Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horváth B (2018). "Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases". Frontiers in Immunology. 9: 248. doi:10.3389/fimmu.2018.00248. PMC 5827539. PMID 29520266.
  17. He Y, Shimoda M, Ono Y, Villalobos IB, Mitra A, Konia T, Grando SA, Zone JJ, Maverakis E (June 2015). "Persistence of Autoreactive IgA-Secreting B Cells Despite Multiple Immunosuppressive Medications Including Rituximab". JAMA Dermatology. 151 (6): 646–50. doi:10.1001/jamadermatol.2015.59. PMID 25901938.
  18. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J (July 2008). "Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study". BMJ. 337: a180. doi:10.1136/bmj.a180. PMC 2483869. PMID 18614511.

External links

External resources